Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.05 USD | -1.58% | -8.47% | -26.36% |
04-30 | Ladenburg Thalmann Starts Marker Therapeutics With Buy Rating, $11 Price Target | MT |
03-27 | North American Morning Briefing : Stocks Edge -2- | DJ |
Sales 2022 | 9.01M 12.42M | Sales 2023 | 3.31M 4.56M | Capitalization | 48.89M 67.34M |
---|---|---|---|---|---|
Net income 2022 | -29M -39.94M | Net income 2023 | -8M -11.02M | EV / Sales 2022 | 2.06 x |
Net cash position 2022 | 4.17M 5.74M | Net cash position 2023 | 15.11M 20.81M | EV / Sales 2023 | 10.2 x |
P/E ratio 2022 |
-0.74
x | P/E ratio 2023 |
-5.88
x | Employees | 8 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 87.85% |
Latest transcript on Marker Therapeutics, Inc.
1 day | -1.58% | ||
1 week | -8.47% | ||
1 month | -5.81% | ||
3 months | -12.72% | ||
6 months | +68.75% | ||
Current year | -26.36% |
Managers | Title | Age | Since |
---|---|---|---|
Juan F. Vera
CEO | Chief Executive Officer | 44 | 18-10-16 |
Monic Stuart
CTO | Chief Tech/Sci/R&D Officer | - | - |
Gerald Garrett
CTO | Chief Tech/Sci/R&D Officer | 59 | 19-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 63 | 18-10-16 | |
Steven Elms
BRD | Director/Board Member | 60 | 19-08-05 |
Katharine Knobil
BRD | Director/Board Member | 60 | 21-12-07 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 4.05 | -1.58% | 28,440 |
24-04-29 | 4.115 | -4.08% | 13,097 |
24-04-26 | 4.29 | -1.72% | 12,576 |
24-04-25 | 4.365 | -0.80% | 3,381 |
24-04-24 | 4.4 | -0.56% | 9,988 |
Delayed Quote Nasdaq, April 30, 2024 at 04:00 pm
More quotes1st Jan change | Capi. | |
---|---|---|
-26.36% | 36.68M | |
+0.17% | 42.86B | |
+10.92% | 42.74B | |
+44.30% | 41.36B | |
-6.20% | 27.68B | |
+5.23% | 25.15B | |
-24.79% | 18.63B | |
+26.69% | 12.37B | |
-3.13% | 11.92B | |
+6.57% | 11.21B |
- Stock Market
- Equities
- MRKR Stock